Specifically, 5‐HT4R agonists inhibit the proliferation, migration, and invasion of glioma cells; promote the apoptosis and autophagy of glioma cells; and significantly increase the expression of Beclin1 and LC3‐II [252]. This evidence concerns the gene BECN1 and central nervous system cancer.